Summary
Thermo Fisher Scientific Inc. (TMO) reported solid financial results for the first quarter of 2016, with total revenues increasing by 10% year-over-year to $4.29 billion. This growth was driven by strong performance across its four business segments, particularly Life Sciences Solutions and Laboratory Products and Services, with contributions from both organic growth and strategic acquisitions. Net income rose to $402.2 million, or $1.01 per diluted share, up from $385.1 million, or $0.96 per diluted share, in the prior year's quarter. The company demonstrated effective cash flow generation, with operating activities providing $289.1 million. Significant strategic investment is evident through the $1.34 billion acquisition of Affymetrix, Inc., which is expected to expand its cellular and genetic analysis capabilities. Financially, Thermo Fisher maintains a robust balance sheet. While short-term debt saw an increase due to funding the Affymetrix acquisition, the company also successfully issued new long-term debt. The company’s cash and cash equivalents significantly increased to $826.8 million. Management expresses confidence in its ability to meet future cash requirements through existing cash, operational cash flow, and available credit facilities, underscoring a stable liquidity position. Investors should note the ongoing integration of acquisitions and strategic investments as key drivers for future performance.
Financial Highlights
56 data points| Revenue | $4.29B |
| Cost of Revenue | $1.93B |
| Gross Profit | $1.96B |
| R&D Expenses | $176.50M |
| SG&A Expenses | $1.21B |
| Operating Expenses | $3.78B |
| Operating Income | $517.90M |
| Interest Expense | $106.20M |
| Net Income | $402.00M |
| EPS (Basic) | $1.02 |
| EPS (Diluted) | $1.01 |
| Shares Outstanding (Basic) | 395.80M |
| Shares Outstanding (Diluted) | 398.70M |
Key Highlights
- 1Total revenues increased 10% to $4.29 billion in Q1 2016, compared to $3.92 billion in Q1 2015, driven by organic growth and acquisitions.
- 2Net income rose to $402.2 million ($1.01 per diluted share) from $385.1 million ($0.96 per diluted share) year-over-year.
- 3The company completed the acquisition of Affymetrix, Inc. for $1.34 billion to enhance its cellular and genetic analysis offerings.
- 4Cash provided by operating activities significantly improved to $289.1 million from $80.0 million in the prior year's quarter.
- 5Cash and cash equivalents increased substantially to $826.8 million from $452.1 million at the end of the previous year.
- 6Total assets grew to $42.95 billion from $40.83 billion, with a notable increase in Goodwill and Acquisition-related Intangible Assets.
- 7Short-term obligations increased significantly to $3.38 billion from $1.05 billion, primarily due to debt financing for acquisitions.